Reactogenicity and immunogenicity of a new formulation of the cuban conjugated vaccine against Haemophilus influenzae type b (QuimiHib(R)) adjuvated in aluminium phosphate in healthy infants. A controlled, randomized, doubled blinded clinical trial

Trial Profile

Reactogenicity and immunogenicity of a new formulation of the cuban conjugated vaccine against Haemophilus influenzae type b (QuimiHib(R)) adjuvated in aluminium phosphate in healthy infants. A controlled, randomized, doubled blinded clinical trial

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Aluminium phosphate; Hib vaccine conjugate
  • Indications Haemophilus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Jul 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry.
    • 23 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top